Open Beta
TREN
MetriLume
TREN

US marketsACRS

SEC-sourced researchBeta

ACRS

Aclaris Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001557746
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 21, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 18,720,000.0000 USD; December 2025: 7,826,000.0000 USD18.7M USD0 USD0December 2024December 2025
ACRS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202418,720,000.0000Feb 26, 2026
December 20257,826,000.0000Feb 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20257,826,000.0000-64,923,000.0000-47,113,000.0000160,460,000.000057,378,000.0000Feb 26, 2026
December 202418,720,000.0000-132,065,000.0000-20,075,000.0000220,327,000.000064,773,000.0000Feb 26, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

33/100
Profitability0
Growth0
Balance sheet64
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$7.83MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$18.72MJan 1, 2024 – Dec 31, 2024Feb 26, 202610-K
Net incomeNetIncomeLoss-$64.92MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$47.11MJan 1, 2025 – Dec 31, 2025Feb 26, 202610-K
Total assetsAssets$160.46MDec 31, 2025Feb 26, 202610-K
Total liabilitiesLiabilities$57.38MDec 31, 2025Feb 26, 202610-K

New filings

Explore methodology ↗